...
首页> 外文期刊>The American journal of clinical nutrition. >Short-term modified alternate-day fasting: a novel dietary strategy for weight loss and cardioprotection in obese adults.
【24h】

Short-term modified alternate-day fasting: a novel dietary strategy for weight loss and cardioprotection in obese adults.

机译:Short-term modified alternate-day fasting: a novel dietary strategy for weight loss and cardioprotection in obese adults.

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: The ability of modified alternate-day fasting (ADF; ie, consuming 25 of energy needs on the fast day and ad libitum food intake on the following day) to facilitate weight loss and lower vascular disease risk in obese individuals remains unknown. OBJECTIVE: This study examined the effects of ADF that is administered under controlled compared with self-implemented conditions on body weight and coronary artery disease (CAD) risk indicators in obese adults. DESIGN: Sixteen obese subjects (12 women, 4 men) completed a 10-wk trial, which consisted of 3 phases: 1) a 2-wk control phase, 2) a 4-wk weight loss/ADF controlled food intake phase, and 3) a 4-wk weight loss/ADF self-selected food intake phase. RESULTS: Dietary adherence remained high throughout the controlled food intake phase (days adherent: 86) and the self-selected food intake phase (days adherent: 89). The rate of weight loss remained constant during controlled food intake (0.67 +/- 0.1 kg/wk) and self-selected food intake phases (0.68 +/- 0.1 kg/wk). Body weight decreased (P < 0.001) by 5.6 +/- 1.0 kg (5.8 +/- 1.1) after 8 wk of diet. Percentage body fat decreased (P < 0.01) from 45 +/- 2 to 42 +/- 2. Total cholesterol, LDL cholesterol, and triacylglycerol concentrations decreased (P < 0.01) by 21 +/- 4, 25 +/- 10, and 32 +/- 6, respectively, after 8 wk of ADF, whereas HDL cholesterol remained unchanged. Systolic blood pressure decreased (P < 0.05) from 124 +/- 5 to 116 +/- 3 mm Hg. CONCLUSION: These findings suggest that ADF is a viable diet option to help obese individuals lose weight and decrease CAD risk. This trial was registered at clinicaltrials.gov as UIC-004-2009.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号